جست‌وجوی استاد و پژوهشگر

Patrick Varga Weiszمشاهده پروفایل

مدرس ارشد

• Microbiota-Gene Interaction
• Epigenetic Regulation
• Gut Epithelial Cell Biology
• +۳ مورد دیگر

Dr. Patrick Varga Weisz is a Senior Lecturer at the School of Life Sciences of the University of Essex . His research focuses on the interplay between gut microbiota and gene regulation in epithelial cells, exploring how microbiota influence host biology and vice versa. His work bridges epigenetics, microbiome research, and inflammatory disorders. Research interests include chromatin dynamics, microbiota-host interactions, and epigenetic mechanisms in disease . Key areas of investigation involve the role of histone modifications, microbiome composition, and dietary interventions in shaping gut health. Recent studies highlight the significance of short-chain fatty acids and microbiota-derived metabolites in modulating chromatin states. Publications reflect a strong focus on microbiota-epithelium signaling, epigenetic regulation in inflammatory bowel diseases, and chromatin remodeling factors . Articles span topics like histone propionylation, Drosophila gut development, and microbiome-driven inflammation. His lab also investigates the role of Smarcad1 in immune responses and aging-related changes in gut epithelial gene expression. Grants and funding sections are listed on his profile but lack specific details. He supervises research projects and teaches courses related to molecular biology and microbiology. His work has implications for therapeutic strategies targeting the gut microbiome and epigenetic interventions in disease. His lab is part of the Colchester Campus, contributing to interdisciplinary research within the School of Life Sciences, emphasizing collaborative studies on host-microbiota interactions and translational epigenetics.

Alejandro Aballayمشاهده پروفایل

استاد

• Genetics
• Immunology
• Neuroscience
• +۳ مورد دیگر

Alejandro Aballay, Ph.D., is a Professor at The University of Texas MD Anderson Cancer Center and McGovern Medical School at UTHealth Houston . His research focuses on the intersection of genetics, immunology, and neuroscience , investigating how the nervous system regulates immune responses against microbial pathogens. Departments: Genetics (MD Anderson), Microbiology and Molecular Genetics (UTHealth Houston) Key Research: Neural control of stress and immune pathways, neuroendocrine signaling in immunity, and mechanisms linking inflammation to diseases like cancer and Alzheimer’s. Scientific Contributions: Recent articles highlight discoveries in GPCR signaling, Wnt pathways, and transcriptional regulators that modulate immunity-longevity tradeoffs and infection resistance. His work employs Caenorhabditis elegans to uncover conserved mechanisms relevant to human health.

Michela Fagioliniمشاهده پروفایل

پژوهشگر

• Neurodevelopmental Disorders
• Critical Period Plasticity
• Neuroscience
• +۷ مورد دیگر

Michela Fagiolini, PhD, is a researcher affiliated with Boston Children's Hospital and Harvard Medical School. She holds academic appointments in the Department of Neurology and the F.M. Kirby Neurobiology Center, focusing on neurodevelopmental disorders. Her work bridges molecular, electrophysiological, and behavioral analyses to study cortical plasticity mechanisms in conditions like Rett Syndrome and autism spectrum disorders (ASD). Education: She earned her M.S. in Biological Sciences from the University of Pisa, Italy, and her Ph.D. in Neurobiology from Scuola Normale Superiore, Italy. After a postdoctoral fellowship at UCSF under Dr. Michael P. Stryker, she joined the Laboratory for Neuronal Circuit Development at Japan's Brain Science Institute, collaborating with Dr. Takao K. Hensch. Research Interests: Dr. Fagiolini explores how sensory experiences shape early brain development and critical periods. Her lab investigates Excitatory/Inhibitory (E/I) circuit dysregulation in neurodevelopmental disorders, leveraging mouse models and human cerebral organoids. Recent studies emphasize therapeutic strategies to restore cortical function by targeting E/I circuit imbalances. She also develops novel biomarkers like fNIRS and transparent microelectrode arrays to assess neural deficits non-invasively. Publications Trends: Her work spans 30+ years, with recent focus on Rett Syndrome biomarkers, autism subtypes via fMRI, and CDKL5 deficiency mechanisms. Earlier contributions include foundational studies on NMDA receptor regulation, critical period plasticity in visual cortex, and the role of epigenetic factors in neurodevelopmental processes. Advising & Grants: While no formal advisees are listed, her research has been supported by grants exploring therapeutic interventions and biomarker development. She collaborates widely, including with the FANTOM consortium for large-scale transcriptomic studies. Labs & Teams: She leads projects within the Intellectual and Developmental Disabilities Research Center and F.M. Kirby Neurobiology Center, which integrate multidisciplinary approaches to neurodevelopmental disorder research.

Huiqing Zhouمشاهده پروفایل

استادیار

• Epitranscriptomics
• RNA Modifications
• Nucleic Acid Chemistry
• +۴ مورد دیگر

Huiqing (Jane) Zhou is an Assistant Professor of Chemistry at Boston College, affiliated with the Morrissey College of Arts and Sciences and the Chemistry Department. Her research focuses on developing technologies to map and modulate RNA chemical modifications (epitranscriptome) in mammalian systems. She employs interdisciplinary approaches including directed evolution, biochemistry, mass spectrometry, and structural biology to study the regulatory mechanisms of these modifications in gene expression and disease. Education: B.S., Nankai University Ph.D., Duke University Research Interests: Her lab explores how RNA modifications influence transcript stability, interactions, and expression, with applications in disease modeling and gene therapy. Key areas include base-resolution mapping of modifications, engineering tools for modification manipulation, and understanding dysregulated epitranscriptomes in diseases like Alzheimer’s. Publications: Her work spans publications in Nature Methods , Biochemistry , and Nucleic Acids Research , focusing on reverse transcriptase evolution, Hoogsteen base pairing dynamics, and RNA modification detection technologies. Awards: 2017 Chicago Fellows Fellowship. Lab & Funding: Supported by Boston College and grants from the National Institutes of Health (NIGMS, NCI). Her lab develops cutting-edge tools to visualize and modulate RNA modifications, aiming to identify novel drug targets and advance gene therapy strategies.

Sweta Raniمشاهده پروفایل

مدرس

• Ocular Therapeutics
• Biomarker Discovery
• Drug Resistance Mechanisms
• +۳ مورد دیگر

Dr. Sweta Rani is a Lecturer in the Department of Science at South East Technological University, leading research in ocular therapeutics and biomarker discovery. Her work focuses on age-related macular degeneration (AMD), dry eye disease, and cancer therapeutics, with expertise in extracellular vesicle biology and nanomedicine approaches. Research integrates molecular diagnostics, drug delivery systems, and patient-centered approaches. Current projects investigate combination therapies for AMD, nanoparticle-based ocular drug delivery, and miRNA biomarkers in disease progression and treatment response. She directs studies on immune modulation in wet AMD using glatiramer acetate. Honors include the Barcroft Medal from Royal Academy of Medicine in Ireland, Best Business Opportunity Award, and Irish Association for Cancer Research Travel Award. With an h-index of 20 and over 3,200 citations, she has published 25+ peer-reviewed articles and contributed to 7 book chapters.

• Neuroscience
• Prosocial Behavior
• Empathy
• +۳ مورد دیگر

Ye Wu is an Assistant Professor in Neurobiology and Biological Chemistry at UCLA's School of Medicine. Her laboratory investigates the neural mechanisms underlying empathy and prosocial behavior using interdisciplinary approaches including single-cell transcriptomics, in vivo calcium imaging, and machine learning. Her research has three primary objectives: 1) Decoding neural computations in prosocial interactions, 2) Mapping neural circuitry controlling prosocial behaviors, and 3) Examining disruptions in psychiatric models. Recent work identifies cortical regulation of helping behaviors, amygdala-hypothalamus reward circuits, and neural control of affiliative touch. Wu's research integrates molecular and systems neuroscience to bridge gaps between cellular mechanisms and complex social behaviors. Her work on autism spectrum disorder revealed widespread transcriptomic dysregulation across the cerebral cortex. Brain & Behavior Research Foundation Young Investigator Award (2024) UCLA Collaboratory Fellowship (2017) Stanford Graduate Fellowship (2007-2010)

Zeribe Nwosuمشاهده پروفایل

استادیار

• Cancer Metabolism
• Pancreatic Cancer
• Therapeutic Targeting
• +۷ مورد دیگر

Zeribe Nwosu is an NIH Cornell Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Assistant Professor in the Department of Molecular Biology and Genetics at Cornell University. His research focuses on cancer metabolism, particularly pancreatic cancer, with emphasis on nutrient utilization, tumor microenvironment interactions, and therapeutic strategies to disrupt metabolic pathways. He holds a PhD in Molecular and Cellular Biology from the University of Heidelberg, Germany, and completed postdoctoral training at the University of Michigan, where he studied pancreatic cancer metabolism. Education: Bachelor of Medical Laboratory Science, Ebonyi State University, Nigeria (2007) MSc in Biomedical Science, London Metropolitan University, UK (2012) PhD in Molecular and Cellular Biology, University of Heidelberg, Germany (2017) Postdoctoral Research Fellow, University of Michigan, USA (2023) Research Interests: Identification of nutrient transporters and metabolic regulators in cancer cells Role of glutathione (GSH) in pancreatic cancer survival and drug resistance Impact of metabolic diseases (e.g., diabetes) on cancer progression Development of novel drug combinations targeting metabolic vulnerabilities Integration of functional genomics and drug screening for therapeutic discovery Awards & Funding: NIH K99/R00 Pathway to Independence Award (2023) AACR Scholar-in-Training Award (2023) Funded by NIH/NCI, Cornell University, and the FIRST program Labs & Teams: The Nwosu Lab utilizes cutting-edge technologies including metabolomics, CRISPR/Cas9, Seahorse analysis, and mouse models to study cancer metabolism. Key collaborations involve bioinformatics and clinical translation.

Harvey Cantorمشاهده پروفایل

استاد

• Immunology
• Cancer Immunology
• Autoimmunity
• +۴ مورد دیگر

Harvey Cantor is a Professor of Immunology at the Dana-Farber Cancer Institute, Harvard University. His research focuses on T-cell subset development, regulatory T cells, and immune regulation in cancer, autoimmunity, and neurodegenerative diseases like Alzheimer's. His laboratory investigates MHC class I and II molecules' roles in T-cell lineage specification and the mechanisms by which regulatory T cells suppress autoimmune and anti-tumor immunity. Key contributions include defining Helios-dependent stabilization of regulatory T cells and identifying Qa-1-restricted CD8+ T regulatory cells' roles in immune tolerance and transplantation. Research highlights include studies on osteopontin's role in immune cell differentiation, the tumor microenvironment, and mechanisms underlying immune checkpoint resistance. Cantor's work bridges immunology and neurobiology, exploring microglial subsets in Alzheimer's pathogenesis. His lab develops novel immunotherapies targeting regulatory T cell reprogramming and checkpoint inhibitors. Recent publications emphasize therapeutic strategies using IL-23R antagonists and EZH2 inhibitors to enhance anti-tumor immunity, as well as Qa-1-based approaches for autoimmune disease modulation. Cantor collaborates widely, with studies published in Nature , Science , and Proceedings of the National Academy of Sciences .

• Gene Regulation
• Nucleic Acids
• G-quadruplexes
• +۴ مورد دیگر

Nicole Smith is a Senior Lecturer at the University of Western Australia (UWA) in the School of Molecular Sciences and a member of the Australian Centre for RNA Therapeutics in Cancer. Her research focuses on non-canonical nucleic acid structures, including G-quadruplexes and i-Motifs, in diseases such as cancers, dementias, and neurodegenerative disorders. She holds a PhD from UWA (2010) and has conducted postdoctoral research at institutions like the Institut Européen de Chimie et Biologie (Bordeaux, France) and The Australian National University. Education: B.Sc. (Biochemistry & Chemistry, University of Sydney), PhD (University of Western Australia) Postdoctoral roles: ANR Fellowship (IECB, France), ANU (Australia) Her research interests span Biochemistry, Chemical Biology, Biophysics, and Genomics. She investigates the role of nucleic acid structures in disease mechanisms, with a focus on therapeutic applications. Key projects include targeting G-quadruplex DNA in Alzheimer’s and breast cancer, and developing nanotechnology-based therapies for neurotrauma. Dr. Smith has secured over 28 grants, including a NHMRC Dementia Fellowship (2017), National Breast Cancer Foundation Innovator Grant (2017), and leadership in the ARC Training Centre for Next-Gen Biomedical Analysis. Her work contributes to UN SDGs 3 (Good Health) and 9 (Industry Innovation). She has supervised numerous students, including 6 PhD graduates, 10 Masters students, and 9 Honours students, alongside exchange scholars from the University of Bath and others. Awards include the Healy Research Collaboration Award (2015) and a visiting professorship at Università Degli Studi di Padova (2021). Labs/Teams: Australian Centre for RNA Therapeutics in Cancer, collaborations in nanomedicine, neuroscience, and drug delivery.

Timothy D. Craggsمشاهده پروفایل

مدرس ارشد

• Single-Molecule Spectroscopy
• Chemical Biology
• Biophysics
• +۴ مورد دیگر

Dr Timothy D. Craggs is a Senior Lecturer in Biological Chemistry at the University of Sheffield's School of Mathematical and Physical Sciences. He holds a MSci from the University of Cambridge (2002) and a PhD from Cambridge (2007). His career includes a Lindemann Fellowship at Yale University (2010), followed by senior postdoc roles at Oxford and Bristol. He joined Sheffield in 2016 as a Lecturer in Chemical Biology. His research focuses on single-molecule spectroscopy, particularly using FRET techniques to study biomolecular processes. Key areas include DNA replication/repair mechanisms, protein dynamics, and structural biology. The Craggs Lab develops innovative tools like the open-source smfBox platform, enhancing precision in distance measurements (sub-3 nm) and enabling FRET-driven structural studies. Teaching activities span undergraduate and postgraduate levels, including modules on biopolymers, biomaterials, and interdisciplinary biology-chemistry topics. His work bridges fundamental research with applied challenges such as diagnostic methods for infectious diseases (e.g., Buruli ulcer detection) and structural studies of aberrant DNA diseases. Collaborative efforts include multi-laboratory benchmarking of FRET accuracy and contributions to open-source scientific instrumentation. Current projects emphasize real-time observation of biomolecular interactions and the development of advanced microscopy techniques.

• Plant immunity
• Plant-pathogen interactions
• Synthetic biology
• +۳ مورد دیگر

Prof. Dr. Armin Djamei holds a professorship at the INRES Institute for Plant Pathology at the University of Bonn. His research focuses on the molecular mechanisms of plant-pathogen interactions, particularly studying phytopathogenic fungi and oomycetes. His work integrates cell biology, genetics, and molecular approaches to understand disease mechanisms and develop crop protection strategies. A key focus is the interaction between smut fungi like Ustilago maydis and host plants such as maize, with an emphasis on effector proteins that manipulate plant immunity and hormone signaling pathways. Publications highlight breakthroughs in understanding how fungal effectors target TOPLESS corepressors to disrupt auxin and jasmonate/ethylene signaling, enabling pathogen colonization. His research also explores synthetic biology applications and the role of epigenetics in beneficial plant-microbe interactions. Djamei collaborates across disciplines within the University of Bonn's Transdisciplinary Research Area (TRA) on Life and Health, contributing to innovative strategies for sustainable agriculture and disease resistance engineering. Notable contributions include developing CRISPR-based methods to engineer smut resistance in maize and identifying novel genetic factors in host-pathogen systems. His work bridges fundamental research with applied agricultural solutions, emphasizing translational outcomes for crop protection.

Hardev Pandhaمشاهده پروفایل

استاد

• Medical Oncology
• Urological Oncology
• Oncolytic Virotherapy
• +۳ مورد دیگر

Hardev Pandha is a Professor of Medical Oncology at the University of Surrey, affiliated with the School of Biosciences within the Faculty of Health and Medical Sciences. He specializes in urological oncology and medical oncology, with a focus on translational research in cancer immunotherapy and virotherapy. His clinical and academic career includes roles at institutions such as the Royal Postgraduate Medical School at Hammersmith Hospital, Royal Marsden Hospital, and St George's, University of London. His research explores innovative treatments like oncolytic viruses (e.g., coxsackievirus A21) for bladder cancer, genetic risk assessment for prostate cancer, and immunotherapeutic strategies to combat cancer progression. Key projects include a Phase II trial of a modified vaccinia Ankara-5T4 vaccine for ovarian cancer and studies on EN2 protein as a bladder cancer biomarker. Pandha collaborates internationally, with work published in high-impact journals. His research aims to improve cancer diagnosis, treatment efficacy, and patient outcomes through cutting-edge molecular and immunological approaches. Educational Background Bachelor of Medicine, University of Birmingham PhD in Molecular Oncology (Imperial College London), conducted at Imperial Cancer Research Fund labs Visiting Fellowship at Stanford University Research Interests Pandha’s work spans: Virotherapy: Using coxsackievirus to target bladder cancer with minimal side effects Immunotherapy: Enhancing anti-tumor immunity via combination therapies (e.g., checkpoint inhibitors, histone deacetylase inhibitors) Genetic Risk Modeling: Developing polygenic hazard scores to predict prostate cancer progression Molecular Diagnostics: Identifying biomarkers like EN2 protein for early cancer detection Cancer Biology: Investigating neuroendocrine transdifferentiation in prostate cancer Grants & Collaborations Pandha leads UK-wide clinical trials and collaborates with institutions like Waters Corporation on translational research. His work has been funded by organizations such as Viralytics Ltd and the UK Biobank. Labs & Teams He oversees research teams focused on oncology translational medicine, viroimmunology, and molecular diagnostics within the University of Surrey’s School of Biosciences. His lab investigates tumor microenvironment dynamics and microbiome interactions in bladder cancer.

Kabirul Islamمشاهده پروفایل

دانشیار

• Epigenetics
• Organic Synthesis
• Bioorganic Chemistry
• +۶ مورد دیگر

Kabirul Islam is an Associate Professor in the Department of Chemistry at the University of Pittsburgh, affiliated with the Dietrich School of Arts and Sciences. His research focuses on chemical approaches to understand epigenetic mechanisms in human biology and disease, integrating organic synthesis, bioorganic chemistry, and structural biology. Key projects include developing chemoproteomic tools like interaction-based protein profiling (IBPP) and allele-specific chemical genetics to study epigenetic regulators. Research interests span epigenetic protein interactions, metabolic-epigenetic links (e.g., 2-ketoglutarate-dependent demethylases), and precision medicine targeting epigenetic drivers of cancer and obesity. The Islam Lab employs synthetic chemistry, protein engineering, and advanced spectroscopic methods to modulate and interrogate chromatin modifications. Publications highlight contributions to TET enzyme analysis, histone demethylase inhibition, and photochemical tools for interactome profiling. Ongoing work explores allele-specific modulation of epigenetic machinery and boron-based oligonucleotide delivery systems. Lab activities include mentoring graduate and undergraduate students, postdoctoral researchers, and collaborations across chemistry, biology, and materials science. The group actively seeks to bridge chemical innovation with biomedical applications, emphasizing translational research in epigenetic therapies.

Jordan J. Greenمشاهده پروفایل

استاد

• Nanobiotechnology
• Biomaterials
• Drug Delivery
• +۵ مورد دیگر

Jordan J. Green, PhD, is a Professor in the Department of Biomedical Engineering at Johns Hopkins University, with affiliations to the Whiting School of Engineering and the Johns Hopkins School of Medicine. His research focuses on biomaterials, drug delivery systems, gene therapy, nanobiotechnology, and immunotherapy, with applications in oncology, regenerative medicine, and ophthalmology. His Biomaterials and Drug Delivery Laboratory develops innovative technologies to address unmet clinical needs, such as cancer treatment, immune modulation, and targeted delivery of therapeutics. Key research areas include nanoparticle design for siRNA and DNA delivery, biomimetic artificial antigen-presenting cells for cancer immunotherapy, and suprachoroidal gene delivery for retinal diseases. Dr. Green’s work bridges the chemistry-biology-engineering interface, emphasizing translational applications to improve human health. Recent studies highlight advancements in polymeric nanoparticle formulations, tumor microenvironment engineering, and radiosensitization strategies for glioblastoma. Publications reflect a focus on nanomedicine, immunomodulation, and targeted therapies, with notable contributions to polymeric nanoparticle systems and biomaterial-mediated genetic reprogramming. Collaborations span academia and industry, driving preclinical and clinical translation of technologies. Dr. Green’s group also explores multiplexed immunofluorescence imaging and machine learning for optimizing therapeutic strategies. His lab maintains the Biomaterials and Drug Delivery Laboratory, emphasizing interdisciplinary innovation. While specific awards are not listed, his extensive publication record and leadership in biomedical engineering underscore his contributions to the field.

Jamie Bernardمشاهده پروفایل

دانشیار

• Carcinogenesis Mechanisms
• Environmental Toxicology
• Obesity-Associated Cancer
• +۳ مورد دیگر

Dr. Jamie Bernard is an Associate Professor and Director of the Ph.D. Program in Pharmacology & Toxicology at Michigan State University (MSU), affiliated with the College of Human Medicine. Her research focuses on mechanisms linking environmental exposures, obesity, and carcinogenesis, particularly the role of adipose tissue-derived factors like FGF2 in promoting cancer. She leads the Bernard Lab, which explores chemopreventive agents and inflammatory pathways in obesity-associated malignancies. Dr. Bernard holds a PhD in Pharmacology and Toxicology. Her work spans drug discovery, immune modulation, and translational biomarker development. She teaches courses including PHM 828 Concepts in Carcinogenesis and PHM 802 Pharmacology . Her research highlights include identifying FGF2's role in adiposity-driven breast cancer, UV radiation's effects on immune signaling, and developing high-throughput assays for chemoprevention screening. She collaborates with MSU's Integrated Pharmacological Sciences and Environmental Toxicology programs. Dr. Bernard advises three graduate students and has published extensively in Nature Medicine , Oncogene , and Journal of Investigative Dermatology . Her lab's work aims to translate mechanistic findings into clinical applications for cancer prevention and treatment.